P
316.14
-4.10 (-1.28%)
| 前收盘价格 | 320.24 |
| 收盘价格 | 325.12 |
| 成交量 | 252,273 |
| 平均成交量 (3个月) | 460,851 |
| 市值 | 8,804,762,624 |
| 价格/销量 (P/S) | 953.14 |
| 股市价格/股市净资产 (P/B) | 10.70 |
| 52周波幅 | |
| 利润日期 | 30 Apr 2026 |
| 营业利益率 (TTM) | -2,868.84% |
| 稀释每股收益 (EPS TTM) | -10.66 |
| 季度收入增长率 (YOY) | 1,349.10% |
| 总债务/股东权益 (D/E MRQ) | 0.24% |
| 流动比率 (MRQ) | 8.44 |
| 营业现金流 (OCF TTM) | -163.91 M |
| 杠杆自由现金流 (LFCF TTM) | -90.04 M |
| 资产报酬率 (ROA TTM) | -39.95% |
| 股东权益报酬率 (ROE TTM) | -63.56% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Praxis Precision Medicines, Inc | 看涨 | 看涨 |
AIStockmoo 评分
0.5
| 分析师共识 | 1.5 |
| 内部交易活动 | NA |
| 价格波动 | -4.5 |
| 技术平均移动指标 | 1.0 |
| 技术振荡指标 | 4.0 |
| 平均 | 0.50 |
|
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 0.16% |
| 机构持股比例 | 122.02% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 1,245.00 (HC Wainwright & Co., 293.81%) | 购买 |
| 中 | 505.00 (59.74%) | |
| 低 | 130.00 (Wedbush, -58.88%) | 卖出 |
| 平均值 | 577.88 (82.79%) | |
| 总计 | 6 购买, 1 保留, 1 卖出 | |
| 平均价格@调整类型 | 327.71 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Wolfe Research | 24 Feb 2026 | 500.00 (58.16%) | 购买 | 342.71 |
| Baird | 20 Feb 2026 | 433.00 (36.96%) | 购买 | 335.28 |
| Truist Securities | 20 Feb 2026 | 700.00 (121.42%) | 购买 | 335.28 |
| Wedbush | 20 Feb 2026 | 130.00 (-58.88%) | 卖出 | 335.28 |
| Wells Fargo | 20 Feb 2026 | 305.00 (-3.52%) | 保留 | 335.28 |
| 02 Feb 2026 | 282.00 (-10.80%) | 保留 | 309.11 | |
| Guggenheim | 10 Feb 2026 | 800.00 (153.05%) | 购买 | 320.48 |
| Needham | 04 Feb 2026 | 510.00 (61.32%) | 购买 | 303.34 |
| HC Wainwright & Co. | 30 Jan 2026 | 1,245.00 (293.81%) | 购买 | 314.00 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合